

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

https://marketpublishers.com/r/P5A748975836EN.html

Date: August 2022

Pages: 120

Price: US\$ 3,500.00 (Single User License)

ID: P5A748975836EN

Abstracts

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 33 molecules. Out of which approximately 33 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 2, 1, 1, 8, 5 and 1 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Metastatic Colorectal Cancer, Non-Proliferative Diabetic Retinopathy (NPDR), Retinal Vein Occlusion, Retinopathy, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein



Occlusion, Choroidal Neovascularization, Colorectal Cancer, Corneal Neovascularization, Graves' Ophthalmopathy, Macular Degeneration, Medulloblastoma, Optic Neuropathy, Retinoblastoma, Retinopathy Of Prematurity, Solid Tumor, Unspecified Cancer, Unspecified Ophthalmological Disorders and Uveal Melanoma.

The latest report Placenta Growth Factor - Drugs In Development, 2022, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Placenta Growth Factor (Vascular



Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape



Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Overview

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Companies Involved in Therapeutics Development

Alteogen Inc

Alvotech SA

Amgen Inc

Celltrion Inc

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Cinnagen Co

Formycon AG

GlycoNex Inc

Hexal AG

Huons Global Co Ltd

i2 Pharmaceuticals Inc

Johnson & Johnson

Kidswell Bio Corp

Luye Pharma Group Ltd

Mabwell Shanghai Bioscience Co Ltd

Neuracle Genetics Inc

Ocular Therapeutix Inc

Oncosimis Biotech Pvt Ltd

Oxurion NV

Panolos Bioscience



PharmAbcine Inc

Prestige BioPharma Ltd

Regeneron Pharmaceuticals Inc

Rophibio Inc

Sam Chun Dang Pharm Co Ltd

Samsung Bioepis Co Ltd

Shilpa Medicare Ltd

Synermore Biologics Co Ltd

Zeen Biotechnology Co Ltd

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Drug Profiles

aflibercept - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile



Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action



History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

aflibercept SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

conbercept - Drug Profile

Product Description

Mechanism Of Action

History of Events

KH-906 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NG-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PB-101 - Drug Profile

Product Description

Mechanism Of Action

SL-186 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SL-188 - Drug Profile

Product Description



Mechanism Of Action

History of Events

THR-317 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ziv-aflibercept - Drug Profile

Product Description

Mechanism Of Action

History of Events

ziv-aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

History of Events

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Dormant Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Discontinued Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Product Development Milestones

Featured News & Press Releases

Jul 14, 2022: New antibody therapy shows promising results for advanced, treatment-refractory pediatric brain cancer

Jul 07, 2022: Alvotech initiates patient study for AVT06, a proposed biosimilar for Eylea Jun 29, 2022: EYLEA (aflibercept) injection sBLA for Every 16-week dosing regimen in patients with diabetic retinopathy accepted for FDA review

Apr 25, 2022: Shilpa Medicare receives NoC from RCGM, Dept. of Biotechnology for its Biosimilar Aflibercept

Feb 22, 2022: Bayer Gets Eylea Biosame approval in Japan as it braces for biosimilar debuts

Feb 11, 2022: Regeneron presents encouraging phase 2 results for high-dose aflibercept 8 mg in wet age-related macular degeneration at Angiogenesis Meeting

Nov 10, 2021: Bayer submits Aflibercept for regulatory approval in the EU and Japan for retinopathy of prematurity in premature babies

Aug 25, 2021: Regeneron's aflibercept meets primary goal in Phase II wet AMD trial Jul 27, 2021: Humana Sues Regeneron Over Price Of Eylea Macular Degeneration Drug

May 04, 2021: Sandoz to study biosimilar aflibercept in Phase III AMD trial

Apr 12, 2021: Oncurious reports encouraging data from phase 1 dose escalation study



of TB-403 in paediatric subjects with relapsed or refractory medulloblastoma presented at the American Association for Cancer Research 2021 Annual Meeting

Apr 09, 2021: Kanghong Pharmaceutical stops clinical study of ocular drug Conbercept

Apr 09, 2021: ONCURIOUS presenting clinical and preclinical data at upcoming

American Association for Cancer Research (AACR) 2021 Annual Meeting

Mar 31, 2021: Regeneron's Eylea lowers vision-threatening events in diabetes trial

Mar 28, 2021: Kanghong pharmaceutical: khb-1802 clinical trial suspended in France

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022



I would like to order

Product name: Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule

Type and Key Players, 2022 Update

Product link: https://marketpublishers.com/r/P5A748975836EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P5A748975836EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970